A pilot randomized controlled trial of pioglitazone for the treatment of poorly controlled asthma in obesity

Respiratory Research

Volumn 16, Issue 1, 2015, Pages

  Dixon, Anne E ^c   Subramanian, Meenakumari ^a   DeSarno, Michael ^a   Black, Kendall ^a   Lane, Lisa ^b   Holguin, Fernando ^b  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Fletcher Allen Health Care   (United States)

Author keywords

Asthma; Asthma control; Obesity; Thiazolidinedione

Indexed keywords

CORTICOSTEROID; METHACHOLINE; NITRIC OXIDE; PIOGLITAZONE; PLACEBO; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIASTHMATIC AGENT; BRONCHOCONSTRICTING AGENT; METHACHOLINE CHLORIDE;

ABDOMINAL PAIN; ADULT; AIRWAY REACTIVITY; ARTICLE; ASTHMA; BREATH ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FLUID RETENTION; HEADACHE; HUMAN; LUNG FUNCTION; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; OBESITY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT PARAMETERS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SORE THROAT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; BRONCHIAL HYPERREACTIVITY; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; INHALATION TEST; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VERMONT;

ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; BRONCHOCONSTRICTOR AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG; MALE; METHACHOLINE CHLORIDE; MIDDLE AGED; OBESITY; PILOT PROJECTS; RISK FACTORS; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME; VERMONT; WEIGHT GAIN;

EID: 84960340702     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-015-0303-6     Document Type: Article

References (41)

1. Schatz M, Hsu JW, Zeiger RS, Chen W, Dorenbaum A, Chipps BE, et al. Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2014;133:1549-56.
2. Dixon A. The treatment of asthma in obesity. Expert Rev Respir Med. 2012;6:331-40.
3. Vortmann M, Eisner MD. BMI and health status among adults with asthma. Obesity (Silver Spring). 2008;16:146-52.
4. Boulet LP, Franssen E. Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Respir Med. 2007;101:2240-7.
5. Peters-Golden M, Swern A, Bird SS, Hustad CM, Grant E, Edelman JM. Influence of body mass index on the response to asthma controller agents. Eur Respir J. 2006;27:495-503.
6. Sutherland ER, Goleva E, Strand M, Beuther DA, Leung DY. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med. 2008;178:682-7.
7. Holguin F, Comhair SA, Hazen SL, Powers RW, Khatri SS, Bleecker ER, et al. An association between L-arginine/asymmetric dimethyl arginine balance, obesity, and the age of asthma onset phenotype. Am J Respir Crit Care Med. 2013;187:153-9.
8. Holguin F, Fitzpatrick A. Obesity, asthma, and oxidative stress. J Appl Physiol (1985). 2010;108:754-9.
9. Al-Alwan A, Bates JH, Chapman DG, Kaminsky DA, DeSarno MJ, Irvin CG, et al. The nonallergic asthma of obesity. A matter of distal lung compliance. Am J Respir Crit Care Med. 2014;189:1494-502.
10. Sood A, Shore SA. Adiponectin, leptin, and resistin in asthma: basic mechanisms through population studies. J Allergy (Cairo). 2013;2013:785835.
11. Sideleva O, Suratt BT, Black KE, Tharp WG, Pratley RE, Forgione P, et al. Obesity and asthma: an inflammatory disease of adipose tissue not the airway. Am J Respir Crit Care Med. 2012;186:598-605.
12. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297-307.
13. Benayoun L, Letuve S, Druilhe A, Boczkowski J, Dombret MC, Mechighel P, et al. Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling. Am J Respir Crit Care Med. 2001;164:1487-94.
14. Hammad H, de Heer HJ, Soullie T, Angeli V, Trottein F, Hoogsteden HC, et al. Activation of peroxisome proliferator-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma. Am J Pathol. 2004;164:263-71.
15. Lee KS, Kim SR, Park SJ, Park HS, Min KH, Jin SM, et al. Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice. J Allergy Clin Immunol. 2006;118:120-7.
16. Honda K, Marquillies P, Capron M, Dombrowicz D. Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. J Allergy Clin Immunol. 2004;113:882-8.
17. Woerly G, Honda K, Loyens M, Papin JP, Auwerx J, Staels B, et al. Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J Exp Med. 2003;198:411-21.
18. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902-7.
19. Narala VR, Ranga R, Smith MR, Berlin AA, Standiford TJ, Lukacs NW, et al. Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma. Respir Res. 2007;8:90.
20. Belvisi MG, Mitchell JA. Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease. Br J Pharmacol. 2009;158:994-1003.
21. Richards DB, Bareille P, Lindo EL, Quinn D, Farrow SN. Treatment with a peroxisomal proliferator activated receptor gamma agonist has a modest effect in the allergen challenge model in asthma: a randomised controlled trial. Respir Med. 2010;104:668-74.
22. Spears M, Donnelly I, Jolly L, Brannigan M, Ito K, McSharry C, et al. Bronchodilatory effect of the PPAR-gamma agonist rosiglitazone in smokers with asthma. Clin Pharmacol Ther. 2009;86:49-53.
23. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-71.
24. Betteridge DJ. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. Fundam Clin Pharmacol. 2009;23:675-9.
25. Ferwana M, Firwana B, Hasan R, Al-Mallah MH, Kim S, Montori VM, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med. 2013;30:1026-32.
26. Sood A, Seagrave J, Herbert G, Harkins M, Alam Y, Chiavaroli A, et al. High sputum total adiponectin is associated with low odds for asthma. J Asthma. 2014;51:459-66.
27. Shore SA, Terry RD, Flynt L, Xu A, Hug C. Adiponectin attenuates allergen-induced airway inflammation and hyperresponsiveness in mice. J Allergy Clin Immunol. 2006;118:389-95.
28. Williams AS, Kasahara DI, Verbout NG, Fedulov AV, Zhu M, Si H, et al. Role of the adiponectin binding protein, T-cadherin (Cdh13), in allergic airways responses in mice. PLoS One. 2012;7, e41088.
29. Medoff BD, Okamoto Y, Leyton P, Weng M, Sandall BP, Raher MJ, et al. Adiponectin deficiency increases allergic airway inflammation and pulmonary vascular remodeling. Am J Respir Cell Mol Biol. 2009;41:397-406.
30. Cheng X, Folco EJ, Shimizu K, Libby P. Adiponectin induces pro-inflammatory programs in human macrophages and CD4+ T cells. J Biol Chem. 2012;287:36896-904.
31. Shin JH, Kim JH, Lee WY, Shim JY. The expression of adiponectin receptors and the effects of adiponectin and leptin on airway smooth muscle cells. Yonsei Med J. 2008;49:804-10.
32. Konter JM, Parker JL, Baez E, Li SZ, Ranscht B, Denzel M, et al. Adiponectin attenuates lipopolysaccharide-induced acute lung injury through suppression of endothelial cell activation. J Immunol. 2012;188:854-63.
33. Shore SA, Schwartzman IN, Mellema MS, Flynt L, Imrich A, Johnston RA. Effect of leptin on allergic airway responses in mice. J Allergy Clin Immunol. 2005;115:103-9.
34. Malli F, Papaioannou AI, Gourgoulianis KI, Daniil Z. The role of leptin in the respiratory system: an overview. Respir Res. 2010;11:152.
35. Arteaga-Solis E, Zee T, Emala CW, Vinson C, Wess J, Karsenty G. Inhibition of leptin regulation of parasympathetic signaling as a cause of extreme body weight-associated asthma. Cell Metab. 2013;17:35-48.
36. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-85.
37. Esteghamati A, Noshad S, Rabizadeh S, Ghavami M, Zandieh A, Nakhjavani M. Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: a randomized clinical trial. Regul Pept. 2013;182:1-6.
38. Kapadia SG, Wei C, Bartlett SJ, Lang J, Wise RA, Dixon AE, et al. Obesity and symptoms of depression contribute independently to the poor asthma control of obesity. Respir Med. 2014;108:1100-7.
39. Dixon AE, Clerisme-Beaty EM, Sugar EA, Cohen RI, Lang JE, Brown ED, et al. Effects of obstructive sleep apnea and gastroesophageal reflux disease on asthma control in obesity. J Asthma. 2011;48:707-13.
40. Shore SA, Williams ES, Zhu M. No effect of metformin on the innate airway hyperresponsiveness and increased responses to ozone observed in obese mice. J Appl Physiol (1985). 2008;105:1127-33.
41. Asthma GI. Global Strategy fo Asthma Management and Prevention. 2015.